US FDA’s Strategic Priorities based on Groundbreaking Legislations: 2016 and Beyond
View: 118
Website https://www.compliance2go.com |
Edit Freely
Category Houston
Deadline: February 11, 2016 | Date: February 11, 2016
Venue/Country: Houston, U.S.A
Updated: 2016-01-26 17:44:29 (GMT+9)
Call For Papers - CFP
Industry: Biotechnology , Medical Device , PharmaceuticalThursday February-11-2016 01:00 PM | 02:00 PM - ESTDESCRIPTIONThis presentation is intended to discuss US FDA’s Strategic Priorities based on groundbreaking legislations ? 2016 and Beyond. Since 2009, there have been a lot of changes being implemented at the FDA. Understanding FDA’s strategic priorities for 2016 and beyond can help firms better understand and use the services or regulatory processes what the FDA offers. It is believed that once the firms are familiar with FDA’s regulatory environment and strategic priorities, the firms can prioritize business goals and objectives in view of evolving regulatory science, regulatory plan/strategy including regulatory requirements for product approvals or clearances. Based on new laws, statutes and new regulations, the FDA’s strategic priorities have evolved in implementing the statutory and regulatory requirements. It is imperative that the healthcare industry should understand FDA’s strategic priorities for the year 2016 and beyond so that industry can use the relevant and applicable information to better prioritize business processes in strategic response to the evolving regulatory environments. This presentation will provide great opportunities to improve industry’s awareness for FDA’s strategic priorities while implementing statutory requirements as set out under the recent groundbreaking legislations for 2016 and beyond. In this presentation, the speaker will share FDA’s various programs and strategic priorities for 2016 and beyond.Areas To Be Covered in this Webinar:Groundbreaking LegislationsFDA Regulations Implementing Groundbreaking LegislationsCommon Misconception about Laws, Regulations, and New FDA Guidance DocumentsFDA Programs for Food, Drugs, Biologics and Medical DevicesFDA AccomplishmentsSignificant Items from US Senate to the FDAFDA User FeesFDA Priority AreasRegulatory Science Priorities for DevicesFDA Implementation of Compounding Quality Act Requirements, UDI System and GUDIDFDA Information Technology: Processes and DevelopmentsFDA Goals and Objectives for 2016 and BeyondWho will benefit:Professionals in healthcare industry: drugs, biologics, medical devices/IVDs, combination products, etc.Compliance OfficersRegulatory AffairsClinical AffairsQuality AssuranceLaboratory PersonnelIT ProfessionalsR&DConsultantsContractors/SubcontractorsOther professionals interested in this topicWebinar Includes:Q/A Session with the Expert to ask your questionCopy of PowerPoint slides (PDF print only)60 Minutes Live PresentationCertificate of Attendance
Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.